Skip to content
  • About Impel
    • Impel History
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Collaborations
  • Pipeline
    • Migraine
    • Agitation
    • Parkinsons
  • Our Science
    • POD Technology
    • Publications & Presentations
    • Meetings
    • Clinical Trials
    • Intellectual Property
  • Join Impel
  • Investors
  • Contact
  • About Impel
    • Impel History
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Collaborations
  • Pipeline
    • Migraine
    • Agitation
    • Parkinsons
  • Our Science
    • POD Technology
    • Publications & Presentations
    • Meetings
    • Clinical Trials
    • Intellectual Property
  • Join Impel
  • Investors
  • Contact

Board of Directors

  • Impel History
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Collaborations

Board of Directors

Adrian Adams Headshot
Adrian Adams

Chairman & CEO

H-Stewart-Parker
H. Stewart Parker

Director

Tim-Nelson
Timothy S. Nelson

Director

Diane-Wilfong
Diane Wilfong

Director

David-Allison
David Allison, Ph.D.

5 AM Ventures

Director

Mahendra-Shah
Mahendra G. Shah, Ph.D.

Vivo Capital

Director

Ali-Satvat
Ali Satvat

KKR

Director

CONNECT WITH US
Icon Twitter link to Twitter Icon LinkedIn link to linkedIn

SUBSCRIBE TO NEWSLETTER

Icon Forward Caret link to sign-up for newsletter
Impel Pharmaceuticals Inc. is a Seattle based commercial-stage pharmaceutical company developing first-in-class intranasal drug treatments for central nervous system disorders.

IMPEL, POD, Trudhesa, Trudhesa DIRECT, and the Impel and Trudhesa Logos are trademarks of Impel Pharmaceuticals, Inc. Other trademarks are the property of the respective owner(s).

Impel Pharmaceuticals

201 Elliott Avenue West, Suite 260
Seattle, WA 98119

Phone: 206.568.1466

Privacy Policy

Terms of Service

Social Media Policy

CA Disclosure

© 2022 Impel Pharmaceuticals Inc. All Rights Reserved.

Privacy Policy

Terms of Service

Social Media Policy

CA Disclosure